Mitomycin - Injection Mitomycin - 10mg 1 Injection(s) / Injection Unknown Introduction: Mitomycin is used in the treatment of certain kinds of cancer of pancreas, breast, lung, and stomach. It can be used alone or in combination with some medicines as part of combination chemotherapy. It works by interfering with the growth of cancer cells, which are eventually destroyed. Mitomycin is given as an injection into vein under the supervision of a doctor and should not be self-administered. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You... Uses of Mitomycin: Pancreatic cancerBreast cancerNon-small cell lung cancerStomach cancer Side effects of Mitomycin: Anemia (low number of red blood cells)Decreased white blood cell countIncreased bleeding tendencyLoss of appetiteNauseaVomitingFeeling of discomfortLow blood plateletsWeight lossRash How to use Mitomycin: Your doctor or nurse will give you this medicine. Kindly do not self administer. How Mitomycin works: Mitomycin is an anti-cancer medication. It works by damaging the genetic material (DNA) of the cancer cells and stops their growth and multiplication. Indication: Solid tumours, non-invasive bladder cancer, stomach cancer, pancreas cancer, metastatic breast cancer, advanced cervical cancer, anal carcinoma Administration: IV Preparation Reconstitute with SWI to a concentration of 0.5 mg/mL IV Administration Administer slow IV push by central line only Flush with 5-10 mL of IV solution before & after drug administration Adult Dose: Intravenous Solid tumours The usual dose is in the range of 4-10 mg (0.06-0.15 mg/kg) given at 1-6 weekly intervals depending on whether other drugs are given in combination and on bone marrow recovery. In a number of combination schedules, the dose is 10 mg/m2 of body surface area, the course being repeated at intervals for as long as required. A course ranging from 40-80 mg (0.58-1.2 mg/kg) is often required for a satisfactory response when used alone or in combination. A higher dosage course may be given when used alone or as part of a particular combination schedule and... Child Dose: Safety and efficacy not established Renal Dose: Renal Impairment Serum creatinine >1.7 mg/dL: Avoid use CrCl <10 mL/min: Decrease dose by 25% CAPD: Decrease dose by 25% Contraindication: Hypersensitivity. Patient w/ platelet counts 1.7 mg/dL. Patient w/ substantial prolongation of prothrombin time or bleeding time, coagulation disorders, increased bleeding tendency. Pregnancy and lactation. Mode of Action: Mitomycin is an antineoplastic antibiotic which is enzymatically reduced to its active metabolite w/in susceptible cells. The active metabolite appears to cause cross-linking of DNA (primarily w/ guanine and cytosine pairs). It is also active against gm+ve bacteria and some viruses. Precaution: Patient w/ bone marrow depression, infections including varicella infection. Hepatic or renal impairment. Patient Counselling This drug may cause generalised weakness and lethargy, if affected, do not drive or operate machinery. Monitoring Parameters Repeated haematologic studies (platelet count, leukocyte count, differential, prothrombin time, bleeding time and Hb determinations) are necessary during therapy and for at least 7 wk following discontinuance of the drug. Carefully monitor LFTs and renal function test. Lactation: Not known if excreted in breast milk, do not nurse Side Effect: >10% Hemolytic uremic syndrome (≤15%),Myelosuppression (64%),Nausea/vomiting (14%),Fever (14%) 1-10% Stomatitis (4%),Increased serum creatinine (2%),Mucous membrane toxicity (4%) Frequency Not Defined Fatigue,Pulmonary toxicity,Dyspnea,Cystitis,Interstitial fibrosis,Nephrotoxicity,Amenorrhea,Alopecia Potentially Fatal: Myelosuppression, haemolytic-uraemic syndrome. Interaction: Increased incidence of cardiotoxicity w/ doxorubicin. Potentially Fatal: Increased risk of intravascular haemolysis and renal failure w/ fluorouracil. Increased risk of haemolytic uraemic syndrome w/ tamoxifen. Acute pulmonary toxicity w/ vinca alkaloids (e.g. vinblastine, vinorelbine). Increased bone marrow depressant effects of aclarubicin.